Clinical Trial Update: Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating a chemokine-modulatory regimen for recurrent resectable colorectal cancer was terminated with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Colorectal Cancer, Colorectal Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-09-09